Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

pentostatin (Rx)Brand and Other Names:Nipent, DCF, more...2Deoxycoformycin

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

powder for injection

  • 10mg/vial
more...

Hairy Cell Leukemia

4 mg/sq.meter IV (bolus or infusion) q2Weeks 

Monitor: CBC, serum creatinine

Orphan Indications

Peripheral T-cell lymphomas

Cutaneous T-Cell lymphoma

Chronic lymphocytic leukemia

Orphan indications sponsor

  • SuperGen, Inc; 4140 Dublin Blvd, Suite 200; Dublin, CA 94568

Other Indications & Uses

Off-label: CLL, CML, cutaneous T-cell lymphoma

Safety & efficacy not established

Next

Interactions

Interaction Checker

pentostatin and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Nausea/vomiting (63%)

            Fever (46%)

            Rash (43%)

            Fatigue (42%)

            Leukopenia (22%)

            Pruritus (21%)

            Cough (20%)

            Chills (19%)

            Myalgia (19%)

            Diarrhea (17%)

            Headache (17%)

            Abdominal pain (16%)

            Anorexia (13%)

            Upper respiratory infection (13%)

            Asthenia (12%)

            Stomatitis (12%)

            Dyspnea (11%)

            Rhinitis (11%)

            Immune hypersensitivity reaction (2-11% )

            Neurotoxicity (1-11% )

            1-10%

            Hyponatremia (<3% )

            Renal failure (<3% )

            Pain

            Pharyngitis

            Thrombocytopenia

            Anemia

            Arthralgia

            Elevated LFT's

            Hypersensitivity

            Skin disorders

            Sweating

            Viral infections

            Frequency Not Defined

            Microangiopathic hemolytic anemia

            Neutropenia

            Thrombotic thrombocytopenic purpura

            Previous
            Next

            Warnings

            Black Box Warnings

            The drug should be administered under the supervision of an experienced cancer chemotherapy physician in a facility equipped to diagnose and manage complications

            Do not exceed recommended doses. Nephrotoxicity, hepatotoxicity, CNS, and pulmonary toxicity occurred in phase 1 studies that used higher doses than recommended

            Do not use with concurrent fludarabine because of increased risk of pulmonary toxicity

            Contraindications

            Hypersensitivity

            Concomitant fludarabine: risk of fatal pulmonary toxicity

            Relative: active infections

            Cautions

            Epilepsy, liver dz, bone marrow depression

            Weigh risk/benefit for pts w/ infections

            Withhold if elevated SCr, renal dysfunction

            Withhold or discontinue if evidence of CNS toxicity

            Avoid pregnancy

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: D

            Lactation: not known if excreted in breast milk, do not nurse

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Half-Life: 5.7 hr

            Peak Plasma: 3.2-9.7 ng/mL

            Protein Bound: 4%

            Vd: 42 L

            Clearance: 68 mL/min/sq.meter

            Excretion: urine (30-90%)

            Mechanism of Action

            Inhibits adenosine deaminase -> incr dATP -> inhibits ribonucleotide reductase -> blocks DNA synthesis

            Previous
            Next

            Administration

            IV Compatibilities

            Solution: D5W, NS, LR

            Y-site: fludarabine, melphalan, ondansetron, paclitaxel, sargramostim

            IV Preparation

            Reconstitute 10 mg in 5 mL SWI for a final concentration 2 mg/mL

            May be given by bolus or diluted to 25-50 mL with D5W to reach a final concentration of 0.33-0.16 mg/mL

            IV Administration

            Give 500-1000 mL of D5/½NS before infusion & 500 mL postinfusion

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.